Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 72Multiple Myeloma 70Leukemia, Myeloid, Acute 70Lymphoma, Large B-Cell, Diffuse 61Lymphoma, Non-Hodgkin 58Leukemia, Lymphocytic, Chronic, B-Cell 57Lymphoma 56Melanoma 52Leukemia 52Breast Neoplasms 49Burkitt Lymphoma 48Myelodysplastic Syndromes 44Recurrence 41Lymphoma, Follicular 41Lymphoma, B-Cell 38Lymphoma, Mantle-Cell 37Neuroblastoma 32Ovarian Neoplasms 31Lymphoma, B-Cell, Marginal Zone 27Sarcoma 26Neoplasms 26Carcinoma, Non-Small-Cell Lung 25Hodgkin Disease 24Neoplasm Metastasis 23Triple Negative Breast Neoplasms 18Carcinoma, Renal Cell 18Neoplasms, Plasma Cell 17Hematologic Neoplasms 17Leukemia, Myelomonocytic, Chronic 16Colorectal Neoplasms 16

Interventions

LY3295668 erbumine 3Topotecan 1TAS-119 1Paclitaxel 1Midazolam 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Epilepsy × Cyclophosphamide × Clear all
NCT04106219 2026-04-21

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Eli Lilly and Company

Phase 1 Active not recruiting
71 enrolled
CNS

Epilepsy, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡